Biological Seed Treatment Market by Microbial Type (Bacteria, Fungi), Application Method (Seed Coating, Seed Dressing, Seed Pelleting), Formulation, Crop Type, Sales Channel - Global Forecast 2025-2032
Description
The Biological Seed Treatment Market was valued at USD 1.47 billion in 2024 and is projected to grow to USD 1.71 billion in 2025, with a CAGR of 15.21%, reaching USD 4.59 billion by 2032.
Comprehensive introduction to biological seed treatment principles, crop establishment benefits, and integration into contemporary agronomic and regulatory environments
Biological seed treatments are increasingly recognized as a cornerstone of modern agronomic practice, offering crop protection and plant health benefits while aligning with sustainability and regulatory priorities. As growers and suppliers confront pest resistance, stricter chemical usage rules, and greater demand for residue-free produce, biological approaches based on living microorganisms and biologically derived compounds are gaining prominence across cropping systems. This introduction frames the contemporary drivers of adoption, the types of biological agents in use, and the operational contexts where seed-applied biologicals provide the greatest agronomic leverage.
To set the stage, it is important to understand that biological seed treatments function across multiple pathways: enhancing seed germination and vigor, protecting against seedling pathogens, and modulating early plant-microbe interactions that can influence growth and resilience. These modes of action create tangible advantages during early crop establishment, especially under abiotic stress conditions. Moreover, the expanding toolkit of formulation technologies and application methods has broadened the practical applicability of biologicals, enabling formulators and seed processors to tailor products to seed types and planting systems. Consequently, stakeholders from breeders to distributors are re-evaluating product portfolios and operational processes to capture the potential of biological seed treatments in a changing agricultural landscape.
Detailed exploration of the key technological, commercial, and supply chain shifts reshaping the adoption and commercialization pathways of biological seed treatments
The landscape for biological seed treatment is undergoing transformative shifts driven by scientific advances, stakeholder expectations, and structural changes across the supply chain. Innovations in microbial screening, genomics, and high-throughput phenotyping have accelerated the identification of strains and consortia with targeted modes of action, while improved formulation science has reduced compatibility issues and enhanced shelf life. These technical developments are complemented by evolving grower priorities; risk-averse producers increasingly value input approaches that reduce chemical residues and support integrated pest management strategies, creating new demand vectors for seed-applied biologicals.
Simultaneously, supply chain actors are adapting to a more complex product set that includes living organisms, requiring updated storage, handling, and quality assurance protocols. Seed processors are investing in coating and pelleting infrastructure to ensure uniform application and performance, and distributors are reconsidering logistics and training to preserve biological efficacy. As a result, business models are shifting from one-time product sales toward service-oriented propositions that combine product, application support, and agronomic advisory. These converging trends point toward a maturation of the segment where scientific validation, regulatory clarity, and operational readiness become the critical determinants of commercial success.
Examination of the 2025 United States tariff adjustments and their cascading operational, procurement, and supply chain impacts on biological seed treatment stakeholders
Tariff policy shifts in the United States in 2025 introduced a layer of complexity for international supply chains that support biological seed treatment development and distribution. Changes in import duties affected inputs ranging from carrier oils and excipients to specialty packaging and certain laboratory consumables, prompting manufacturers and distributors to reassess sourcing strategies and total landed costs. While many biological active ingredients are produced domestically, critical upstream materials and specialized equipment often cross borders, making tariff-induced cost pressures a tangible operational concern for firms operating global supply chains.
In response, several organizations accelerated reshoring or nearshoring initiatives to mitigate exposure to cross-border tariff volatility. This transition required capital investment and supplier qualification work, which in turn influenced project timelines and product rollout schedules. Importantly, firms that proactively diversified supplier bases and invested in flexible production arrangements were better positioned to absorb cost fluctuations without disrupting customer supply. The tariff landscape also highlighted the strategic value of regulatory alignment and bilateral agreements that reduce trade friction, reinforcing the case for closer collaboration between commercial, procurement, and policy teams when designing long-term commercialization strategies.
In-depth segmentation insights linking microbial classes, application methods, formulations, crop targets, and sales channels to product design and go-to-market strategies
Understanding product and customer segmentation is essential for designing development and commercialization pathways that resonate with diverse end users. When considered through the lens of microbial type, the landscape differentiates between bacterial and fungal solutions, each with distinct modes of action, formulation challenges, and regulatory considerations. These biological classes inform research priorities and commercial positioning because efficacy profiles and compatibility with seed treatments vary significantly between bacteria and fungi.
Application method segmentation further shapes product design and adoption dynamics, encompassing seed coating, seed dressing, and seed pelleting approaches. Within seed coating, there are technical distinctions between encrusting and film coating techniques that influence active loading, seed flow characteristics, and planter compatibility. Formulation choices intersect with these methods, as product developers select among granule, liquid, and powder presentations; liquid formulations bring a secondary layer of complexity because they can be oil based or water based, which affects carrier interactions and drying profiles. Crop type segmentation clarifies target agronomic systems, with cereals, fruits and vegetables, and oilseeds and pulses each presenting unique planting densities, seed sizes, and disease pressures. Cereals themselves break down into corn, rice, and wheat, while oilseeds and pulses include rapeseed, soybean, and sunflower, all of which require tailored seed treatment strategies. Finally, sales channel segmentation between offline and online distribution channels has implications for packaging, shelf communication, and customer education, since adoption pathways and technical support expectations differ between traditional distributors and digital platforms. Taken together, these segmentation layers guide product development teams to prioritize traits that align with specific cultivar requirements, handling workflows, and purchaser preferences.
Strategic regional insights on regulatory frameworks, agronomic needs, and distribution channels across the Americas, Europe Middle East & Africa, and Asia-Pacific regions
Regional dynamics exert a strong influence on the adoption and commercialization of biological seed treatments, with distinct regulatory, agronomic, and commercial conditions across major geographies. In the Americas, agricultural systems range from large-scale commodity row crops with mechanized planting to specialist high-value horticulture, and regulatory frameworks increasingly support biopesticide registrations that facilitate adoption. These conditions drive a focus on operational scalability, compatibility with high-throughput seed processing, and commercial models that address broad row-crop applications as well as niche vegetable and fruit segments.
Across Europe, Middle East & Africa, regulatory stringency and public interest in sustainable inputs are prominent drivers. The region's varied climates and cropping systems place a premium on localized efficacy data and tailored agronomic support. In contrast, the Asia-Pacific region presents a heterogeneous opportunity set driven by intensive rice and cereal systems, smallholder planting practices, and rising interest in yield-protection technologies that reduce post-planting losses. This diversity necessitates differentiated approaches to formulation, packaging, and distribution, and it underscores the importance of localized trials, farmer education, and partnerships with seed companies and extension networks to achieve meaningful uptake.
Key company-level dynamics that distinguish leaders through integrated R&D, formulation excellence, strategic partnerships, and operational capabilities
The competitive landscape for biological seed treatments is characterized by an interplay of specialized biotechnology firms, traditional agrochemical companies expanding into biologicals, and seed enterprises integrating treatments into proprietary offerings. Firms that combine deep microbial R&D capabilities with robust formulation and seed processing expertise have an edge in translating laboratory discoveries into reliable, seed-applied products. Strategic partnerships between small innovators and larger distribution networks are common, enabling novel actives to reach commercial scale while leveraging established sales channels and regulatory experience.
Additionally, companies that invest in demonstration trials and stakeholder education create stronger trust signals with growers and seed companies, facilitating adoption. Intellectual property considerations around strains, formulations, and application methods also shape competitive dynamics, favoring organizations that can protect core assets while fostering collaborative research arrangements. Finally, capacity in quality control, cold-chain or humidity-controlled storage, and seed testing drives differentiation, since consistent on-seed performance is critical to establishing long-term credibility with commercial seed suppliers and end users.
Actionable strategic and operational recommendations for companies to accelerate adoption, ensure product reliability, and scale biological seed treatment offerings effectively
Leaders in the biological seed treatment space should pursue a set of prioritized, actionable initiatives to translate scientific promise into commercial impact. First, aligning R&D pipelines with clearly articulated crop and application priorities will reduce time-to-market friction and improve relevance to seed companies and growers. This involves connecting microbial discovery programs with formulation engineering and seed processing constraints early in the development lifecycle. Next, establishing rigorous field and seed-environment validation programs that generate reproducible performance data across diverse geographies and seed lots will support regulatory submissions and adoption conversations. Such evidence-building must be accompanied by clear protocols for quality assurance and storage to preserve biological activity across distribution networks.
Moreover, firms should strengthen procurement resilience by diversifying suppliers of critical inputs and pursuing flexible manufacturing arrangements that allow for rapid scaling and regional production. Commercially, integrating technical service offerings with product sales enhances value and supports adoption; this can include on-farm demonstrations, digital advisory tools, and seed treater training programs. Finally, proactive engagement with regulators and industry associations can streamline approval pathways and help shape standards that balance innovation with safety and efficacy, thereby reducing downstream barriers to market entry and expansion.
Transparent explanation of the mixed-methods research approach combining expert interviews, technical literature, and cross-validated evidence to underpin conclusions and recommendations
This research synthesized primary interviews with agronomists, seed company technical leads, formulation scientists, and distribution partners alongside secondary literature from peer-reviewed journals, regulatory guidance documents, and industry white papers. The approach prioritized triangulation of qualitative insights with technical data to ensure that conclusions reflect both on-farm realities and laboratory-proven mechanisms. Primary engagements were structured to capture perspectives on efficacy, handling constraints, regulatory hurdles, and commercial acceptance, while secondary sources informed the scientific context for modes of action and formulation considerations.
Throughout the analysis, emphasis was placed on reproducibility and transparency: assumptions and methodological limits were documented, and sensitivity to regional agronomic variability was incorporated by examining case studies across multiple cropping systems. Quality control for the research process included cross-validation of claims with multiple independent sources and the inclusion of subject-matter expert review to surface potential blind spots. This methodology ensures that recommendations are rooted in practicable evidence and balanced judgment rather than single-source assertions.
Summative conclusion emphasizing the scientific potential, operational prerequisites, and strategic pathways needed to mainstream biological seed treatment solutions
In summary, biological seed treatments occupy a strategic position at the intersection of sustainable agriculture, seed technology, and supply chain innovation. Scientific advances in microbial selection and formulation, together with shifting regulatory and grower preferences, create tangible pathways for biologicals to enhance seedling vigor, reduce reliance on conventional chemical treatments, and support integrated crop management approaches. However, realizing this potential requires more than discovery; it demands investment in formulation compatibility, seed processing infrastructure, rigorous validation, and tailored commercialization strategies that respect regional agronomic realities.
Looking ahead, stakeholders that integrate multidisciplinary expertise-combining microbiology, formulation science, seed engineering, and commercial channel development-will be best equipped to convert innovation into broad-scale adoption. By addressing quality assurance across the supply chain, building robust evidence packages, and aligning product attributes with end-user needs, organizations can position biological seed treatments as reliable, scalable tools that contribute to resilient cropping systems.
Please Note: PDF & Excel + Online Access - 1 Year
Comprehensive introduction to biological seed treatment principles, crop establishment benefits, and integration into contemporary agronomic and regulatory environments
Biological seed treatments are increasingly recognized as a cornerstone of modern agronomic practice, offering crop protection and plant health benefits while aligning with sustainability and regulatory priorities. As growers and suppliers confront pest resistance, stricter chemical usage rules, and greater demand for residue-free produce, biological approaches based on living microorganisms and biologically derived compounds are gaining prominence across cropping systems. This introduction frames the contemporary drivers of adoption, the types of biological agents in use, and the operational contexts where seed-applied biologicals provide the greatest agronomic leverage.
To set the stage, it is important to understand that biological seed treatments function across multiple pathways: enhancing seed germination and vigor, protecting against seedling pathogens, and modulating early plant-microbe interactions that can influence growth and resilience. These modes of action create tangible advantages during early crop establishment, especially under abiotic stress conditions. Moreover, the expanding toolkit of formulation technologies and application methods has broadened the practical applicability of biologicals, enabling formulators and seed processors to tailor products to seed types and planting systems. Consequently, stakeholders from breeders to distributors are re-evaluating product portfolios and operational processes to capture the potential of biological seed treatments in a changing agricultural landscape.
Detailed exploration of the key technological, commercial, and supply chain shifts reshaping the adoption and commercialization pathways of biological seed treatments
The landscape for biological seed treatment is undergoing transformative shifts driven by scientific advances, stakeholder expectations, and structural changes across the supply chain. Innovations in microbial screening, genomics, and high-throughput phenotyping have accelerated the identification of strains and consortia with targeted modes of action, while improved formulation science has reduced compatibility issues and enhanced shelf life. These technical developments are complemented by evolving grower priorities; risk-averse producers increasingly value input approaches that reduce chemical residues and support integrated pest management strategies, creating new demand vectors for seed-applied biologicals.
Simultaneously, supply chain actors are adapting to a more complex product set that includes living organisms, requiring updated storage, handling, and quality assurance protocols. Seed processors are investing in coating and pelleting infrastructure to ensure uniform application and performance, and distributors are reconsidering logistics and training to preserve biological efficacy. As a result, business models are shifting from one-time product sales toward service-oriented propositions that combine product, application support, and agronomic advisory. These converging trends point toward a maturation of the segment where scientific validation, regulatory clarity, and operational readiness become the critical determinants of commercial success.
Examination of the 2025 United States tariff adjustments and their cascading operational, procurement, and supply chain impacts on biological seed treatment stakeholders
Tariff policy shifts in the United States in 2025 introduced a layer of complexity for international supply chains that support biological seed treatment development and distribution. Changes in import duties affected inputs ranging from carrier oils and excipients to specialty packaging and certain laboratory consumables, prompting manufacturers and distributors to reassess sourcing strategies and total landed costs. While many biological active ingredients are produced domestically, critical upstream materials and specialized equipment often cross borders, making tariff-induced cost pressures a tangible operational concern for firms operating global supply chains.
In response, several organizations accelerated reshoring or nearshoring initiatives to mitigate exposure to cross-border tariff volatility. This transition required capital investment and supplier qualification work, which in turn influenced project timelines and product rollout schedules. Importantly, firms that proactively diversified supplier bases and invested in flexible production arrangements were better positioned to absorb cost fluctuations without disrupting customer supply. The tariff landscape also highlighted the strategic value of regulatory alignment and bilateral agreements that reduce trade friction, reinforcing the case for closer collaboration between commercial, procurement, and policy teams when designing long-term commercialization strategies.
In-depth segmentation insights linking microbial classes, application methods, formulations, crop targets, and sales channels to product design and go-to-market strategies
Understanding product and customer segmentation is essential for designing development and commercialization pathways that resonate with diverse end users. When considered through the lens of microbial type, the landscape differentiates between bacterial and fungal solutions, each with distinct modes of action, formulation challenges, and regulatory considerations. These biological classes inform research priorities and commercial positioning because efficacy profiles and compatibility with seed treatments vary significantly between bacteria and fungi.
Application method segmentation further shapes product design and adoption dynamics, encompassing seed coating, seed dressing, and seed pelleting approaches. Within seed coating, there are technical distinctions between encrusting and film coating techniques that influence active loading, seed flow characteristics, and planter compatibility. Formulation choices intersect with these methods, as product developers select among granule, liquid, and powder presentations; liquid formulations bring a secondary layer of complexity because they can be oil based or water based, which affects carrier interactions and drying profiles. Crop type segmentation clarifies target agronomic systems, with cereals, fruits and vegetables, and oilseeds and pulses each presenting unique planting densities, seed sizes, and disease pressures. Cereals themselves break down into corn, rice, and wheat, while oilseeds and pulses include rapeseed, soybean, and sunflower, all of which require tailored seed treatment strategies. Finally, sales channel segmentation between offline and online distribution channels has implications for packaging, shelf communication, and customer education, since adoption pathways and technical support expectations differ between traditional distributors and digital platforms. Taken together, these segmentation layers guide product development teams to prioritize traits that align with specific cultivar requirements, handling workflows, and purchaser preferences.
Strategic regional insights on regulatory frameworks, agronomic needs, and distribution channels across the Americas, Europe Middle East & Africa, and Asia-Pacific regions
Regional dynamics exert a strong influence on the adoption and commercialization of biological seed treatments, with distinct regulatory, agronomic, and commercial conditions across major geographies. In the Americas, agricultural systems range from large-scale commodity row crops with mechanized planting to specialist high-value horticulture, and regulatory frameworks increasingly support biopesticide registrations that facilitate adoption. These conditions drive a focus on operational scalability, compatibility with high-throughput seed processing, and commercial models that address broad row-crop applications as well as niche vegetable and fruit segments.
Across Europe, Middle East & Africa, regulatory stringency and public interest in sustainable inputs are prominent drivers. The region's varied climates and cropping systems place a premium on localized efficacy data and tailored agronomic support. In contrast, the Asia-Pacific region presents a heterogeneous opportunity set driven by intensive rice and cereal systems, smallholder planting practices, and rising interest in yield-protection technologies that reduce post-planting losses. This diversity necessitates differentiated approaches to formulation, packaging, and distribution, and it underscores the importance of localized trials, farmer education, and partnerships with seed companies and extension networks to achieve meaningful uptake.
Key company-level dynamics that distinguish leaders through integrated R&D, formulation excellence, strategic partnerships, and operational capabilities
The competitive landscape for biological seed treatments is characterized by an interplay of specialized biotechnology firms, traditional agrochemical companies expanding into biologicals, and seed enterprises integrating treatments into proprietary offerings. Firms that combine deep microbial R&D capabilities with robust formulation and seed processing expertise have an edge in translating laboratory discoveries into reliable, seed-applied products. Strategic partnerships between small innovators and larger distribution networks are common, enabling novel actives to reach commercial scale while leveraging established sales channels and regulatory experience.
Additionally, companies that invest in demonstration trials and stakeholder education create stronger trust signals with growers and seed companies, facilitating adoption. Intellectual property considerations around strains, formulations, and application methods also shape competitive dynamics, favoring organizations that can protect core assets while fostering collaborative research arrangements. Finally, capacity in quality control, cold-chain or humidity-controlled storage, and seed testing drives differentiation, since consistent on-seed performance is critical to establishing long-term credibility with commercial seed suppliers and end users.
Actionable strategic and operational recommendations for companies to accelerate adoption, ensure product reliability, and scale biological seed treatment offerings effectively
Leaders in the biological seed treatment space should pursue a set of prioritized, actionable initiatives to translate scientific promise into commercial impact. First, aligning R&D pipelines with clearly articulated crop and application priorities will reduce time-to-market friction and improve relevance to seed companies and growers. This involves connecting microbial discovery programs with formulation engineering and seed processing constraints early in the development lifecycle. Next, establishing rigorous field and seed-environment validation programs that generate reproducible performance data across diverse geographies and seed lots will support regulatory submissions and adoption conversations. Such evidence-building must be accompanied by clear protocols for quality assurance and storage to preserve biological activity across distribution networks.
Moreover, firms should strengthen procurement resilience by diversifying suppliers of critical inputs and pursuing flexible manufacturing arrangements that allow for rapid scaling and regional production. Commercially, integrating technical service offerings with product sales enhances value and supports adoption; this can include on-farm demonstrations, digital advisory tools, and seed treater training programs. Finally, proactive engagement with regulators and industry associations can streamline approval pathways and help shape standards that balance innovation with safety and efficacy, thereby reducing downstream barriers to market entry and expansion.
Transparent explanation of the mixed-methods research approach combining expert interviews, technical literature, and cross-validated evidence to underpin conclusions and recommendations
This research synthesized primary interviews with agronomists, seed company technical leads, formulation scientists, and distribution partners alongside secondary literature from peer-reviewed journals, regulatory guidance documents, and industry white papers. The approach prioritized triangulation of qualitative insights with technical data to ensure that conclusions reflect both on-farm realities and laboratory-proven mechanisms. Primary engagements were structured to capture perspectives on efficacy, handling constraints, regulatory hurdles, and commercial acceptance, while secondary sources informed the scientific context for modes of action and formulation considerations.
Throughout the analysis, emphasis was placed on reproducibility and transparency: assumptions and methodological limits were documented, and sensitivity to regional agronomic variability was incorporated by examining case studies across multiple cropping systems. Quality control for the research process included cross-validation of claims with multiple independent sources and the inclusion of subject-matter expert review to surface potential blind spots. This methodology ensures that recommendations are rooted in practicable evidence and balanced judgment rather than single-source assertions.
Summative conclusion emphasizing the scientific potential, operational prerequisites, and strategic pathways needed to mainstream biological seed treatment solutions
In summary, biological seed treatments occupy a strategic position at the intersection of sustainable agriculture, seed technology, and supply chain innovation. Scientific advances in microbial selection and formulation, together with shifting regulatory and grower preferences, create tangible pathways for biologicals to enhance seedling vigor, reduce reliance on conventional chemical treatments, and support integrated crop management approaches. However, realizing this potential requires more than discovery; it demands investment in formulation compatibility, seed processing infrastructure, rigorous validation, and tailored commercialization strategies that respect regional agronomic realities.
Looking ahead, stakeholders that integrate multidisciplinary expertise-combining microbiology, formulation science, seed engineering, and commercial channel development-will be best equipped to convert innovation into broad-scale adoption. By addressing quality assurance across the supply chain, building robust evidence packages, and aligning product attributes with end-user needs, organizations can position biological seed treatments as reliable, scalable tools that contribute to resilient cropping systems.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
183 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of AI driven predictive models to optimize microbial seed treatment efficacy
- 5.2. Development of microencapsulation techniques for controlled release of beneficial microbes on seeds
- 5.3. Adoption of next generation sequencing to customize seed treatment strains for specific soil microbiomes
- 5.4. Strategic alliances between agrotech startups and major seed companies for co developing bio inoculants
- 5.5. Regulatory harmonization initiatives accelerating global commercialization of microbial seed technologies
- 5.6. Increasing demand for organic certified biological seed treatments in sustainable and regenerative agriculture
- 5.7. Microbiome engineering approaches to enhance crop resilience against drought and heat stress from seed
- 5.8. Innovations in scalable fermentation and formulation processes to reduce production costs of seed inoculants
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Biological Seed Treatment Market, by Microbial Type
- 8.1. Bacteria
- 8.2. Fungi
- 9. Biological Seed Treatment Market, by Application Method
- 9.1. Seed Coating
- 9.1.1. Encrusting
- 9.1.2. Film Coating
- 9.2. Seed Dressing
- 9.3. Seed Pelleting
- 10. Biological Seed Treatment Market, by Formulation
- 10.1. Granule
- 10.2. Liquid
- 10.2.1. Oil Based
- 10.2.2. Water Based
- 10.3. Powder
- 11. Biological Seed Treatment Market, by Crop Type
- 11.1. Cereals
- 11.1.1. Corn
- 11.1.2. Rice
- 11.1.3. Wheat
- 11.2. Fruits & Vegetables
- 11.3. Oilseeds & Pulses
- 11.3.1. Rapeseed
- 11.3.2. Soybean
- 11.3.3. Sunflower
- 12. Biological Seed Treatment Market, by Sales Channel
- 12.1. Offline
- 12.2. Online
- 13. Biological Seed Treatment Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Biological Seed Treatment Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Biological Seed Treatment Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Agrinos AS
- 16.3.2. AMVAC Chemical Corporation
- 16.3.3. BASF SE
- 16.3.4. Bayer AG
- 16.3.5. Bioworks Inc
- 16.3.6. Certis USA LLC
- 16.3.7. Corteva Agriscience
- 16.3.8. East-West Seed
- 16.3.9. FMC Corporation
- 16.3.10. Germains Seed Technology
- 16.3.11. Groupe Limagrain SA
- 16.3.12. Incotec Group BV
- 16.3.13. Italpollina SpA
- 16.3.14. Koppert Biological Systems
- 16.3.15. Marrone Bio Innovations Inc
- 16.3.16. Novozymes A/S
- 16.3.17. Nufarm Limited
- 16.3.18. Plant Health Care plc
- 16.3.19. Rizobacter Argentina S.A.
- 16.3.20. SAKATA SEED CORPORATION
- 16.3.21. Sumitomo Chemical Co Ltd
- 16.3.22. Syngenta AG
- 16.3.23. UPL Limited
- 16.3.24. Valent BioSciences LLC
- 16.3.25. Verdesian Life Sciences LLC
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
